VivoSeq
Other

Skin Disease

44

Pipeline Programs↗

4

Active Trials↗

25

Companies Involved↗

Skin Disease is a moderately active landscape with 44 programs across 25 companies. The most active players are Boehringer Ingelheim, Vitae Pharmaceuticals Inc., an Allergan affiliate, Neurim Pharmaceuticals Ltd.. 16 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 1B

BeOne Medicines

1 program

Phase 1Eli Lilly logo

Eli Lilly

3 programs

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

40 of 45 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody511%

Small molecule leads; the ring shows all 45 classified programs, each share of the total. Modality classified for 100% of 46 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed6 · 43%
Unknown status2 · 14%
Recruiting2 · 14%
Not yet recruiting2 · 14%
Withdrawn1 · 7%
Terminated1 · 7%

Clinical Trials

Trial Activity

14 trials

Determinants of Chronic Inflammatory Skin Disease Trajectories
Recruiting·UUniversity Hospital Schleswig-Holstein·N/A·NCT05928169·1,000 enrolled
Molecular Signatures in Inflammatory Skin Disease
Recruiting·PProf. Dr. Stephan Weidinger·N/A·NCT03358693·300 enrolled
The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07487831·50 enrolled
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
Not yet recruiting·FFondazione ISIDE·N/A·NCT07336641·20,000 enrolled
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Completed·UUniversity of California, San Francisco·Phase 4·NCT04541329·7 enrolled
A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT05728489·64 enrolled
A Study of LY3041658 in Participants With Skin Diseases
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02896868·60 enrolled
Anakinra for Inflammatory Pustular Skin Diseases
Completed·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT01794117·18 enrolled
Fexofenadine in Pruritic Skin Disease
Completed·HHandok Inc.·Phase 4·NCT00261079·435 enrolled
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Completed·LLondon School of Hygiene and Tropical Medicine·Phase 4·NCT02775617·1,291 enrolled
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
Terminated·TThe Cleveland Clinic·Phase 3·NCT01525329·18 enrolled
Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease
Withdrawn·—·Phase 1·NCT04656704
The Safety and Effectiveness of Local Injection of Antihistamines in Treatment of Inflammatory Skin Diseases
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT04937101·78 enrolled
Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases
Unknown status·XXiangya Hospital of Central South University·N/A·NCT05488860·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)